The market for rosuvastatin is set? Zhejiang Haizheng passed the consistency evaluation

According to the China new drug development monitoring database (CPM), Zhejiang Haizheng has become the third enterprise to pass the consistency evaluation of rosuvastatin tablets after Zhengda Tianqing and Zhejiang Jingxin In addition, according to Article 6 of the opinions of the general office of the State Council on the evaluation of the consistency of quality and efficacy of generic drugs (GF [2016] No 8), if more than three manufacturers of the same kind of drugs have passed the consistency evaluation, the varieties that have failed the consistency evaluation will not be used in the centralized purchase of drugs That is to say, the enterprises whose products have not passed the consistency evaluation are afraid that it is difficult to leave According to the China new drug development monitoring database (CPM), ruishuvastatin tablets of Zhejiang Haizheng Pharmaceutical Co., Ltd passed the consistency evaluation of quality and efficacy of generic drugs Rosuvastatin is a selective and competitive HMG CoA reductase inhibitor It is the latest statins, which can effectively reduce blood lipid, reverse atheromatous plaque, reduce the inflammatory index of atherosclerosis, and reduce the incidence of cardiovascular events and mortality in high-risk and low-risk patients It is suitable for primary hypercholesterolemia (type IIA, including heterozygous familial hypercholesterolemia) or mixed type dyslipidemia (type IIB) which can not be properly controlled by diet control and other non drug treatment (such as exercise treatment and weight loss) It is also suitable for homozygous familial hypercholesterolemia as an adjunctive treatment of diet control and other lipid-lowering measures (such as LDL removal therapy), or when these methods are not applicable Rosuvastatin was first developed by yanyeyi company of Japan In April 2007, rosuvastatin was approved to be listed by the State Food and drug administration, marking that rosuvastatin calcium tablet officially entered the Chinese market Rosuvastatin calcium tablets are in great demand in China In the domestic market from 2012 to 2017, the sales volume of rosuvastatin sample hospital increased from 372 million yuan to 1.103 billion yuan, with a compound growth rate of more than 16% in five years Rosuvastatin calcium tablets in the treatment of cardiovascular and cerebrovascular diseases has a very good effect In recent years, the industry has developed rapidly, and gradually become the second largest statins after atorvastatin Good development prospects attracted some domestic enterprises to enter the field of rosuvastatin calcium tablets After 2013, Lunan Beite, Zhengda Tianqing, Zhejiang Jingxin, Zhejiang Haizheng and other enterprises were successively approved to produce the product In Q1 2018, IPR pharmaceuticals has the largest market share of nearly 67%, followed by Lunan Beit, Zhengda Tianqing, and Zhejiang Jingxin, while Zhejiang Hai is in the fourth place The consistency evaluation of risuvastatin tablets in Haizheng, Zhejiang means that the market of risuvastatin tablets has been basically finalized, and other enterprises that fail to pass the consistency evaluation of the drug may not be easy to go in the future That is to say, enterprises such as Lunan Beit and Nanjing Xiansheng may not catch up with the centralized procurement if they do not step up.